Heplisav B

Heplisav B is a prescription‑only hepatitis B surface antigen vaccine that contains recombinant hepatitis B surface antigen (HBsAg) combined with the CpG 1018 adjuvant. It is supplied as an injectable vaccine for intramuscular administration. The product is marketed in the European Union and is classified as a prophylactic vaccine (ATC code J07BC01). It works by stimulating active immunity against hepatitis B virus in healthy adults and individuals at risk.

Heplisav B is indicated for the prevention of hepatitis B virus infection in adults.

- Primary prophylaxis for adults who have not completed a hepatitis B vaccination series. - Immunization of individuals at increased risk, such as healthcare personnel and people with occupational exposure. - Protection for travelers to regions where hepatitis B is endemic. - Use in patients with chronic liver disease or renal failure who require hepatitis B immunity. - Administration to adults who need rapid seroconversion before potential exposure. - Vaccination of adults with immunocompromising conditions who may have reduced response to other hepatitis B vaccines.

The safety profile of Heplisav B reflects the typical reactions observed with injectable hepatitis B vaccines.

Common: - Mild to moderate pain, redness, or swelling at the injection site, usually resolving within a few days without intervention. - Low‑grade fever or chills that may develop within 24 hours after vaccination and generally subside spontaneously. - Transient fatigue, headache, or muscle aches that are self‑limited and often improve with rest or over‑the‑counter analgesics. - Slightly elevated liver enzymes detected in routine laboratory testing, which are usually temporary and not associated with clinical hepatitis. - Mild nausea or gastrointestinal discomfort that may occur shortly after injection and resolves without specific treatment.

Serious: - Immediate hypersensitivity reactions, including anaphylaxis, which can cause hives, respiratory distress, or circulatory collapse and require emergency care. - Rare neurologic events such as Guillain‑Barré syndrome reported after vaccination, requiring prompt medical evaluation.

Precautions for Heplisav B focus on patient assessment, timing of administration, and monitoring for adverse reactions.

- Verify no prior severe allergic reaction to any component of the vaccine. - Assess for acute moderate or severe illness; defer vaccination until recovery. - Consider postponement in pregnant women, as safety data are limited. - Review immunocompromised status; vaccine may be less effective. - Counsel patients to remain for observation after injection to detect immediate reactions. - Avoid concurrent administration with other live vaccines in the same injection site.

Heplisav B may interact with other medicines or vaccines, influencing immune response or safety.

Avoid: - Administration of another hepatitis B vaccine within 4 weeks, which could interfere with immune response. - Concurrent use of immunosuppressive therapy that may markedly reduce vaccine efficacy.

Use with caution: - Co‑administration with other inactivated vaccines is generally acceptable but monitor for increased local reactions. - Use in patients receiving anticoagulants; intramuscular injection may increase bleeding risk. - Consider timing with biologic agents (e.g., TNF‑α inhibitors); schedule vaccination before initiating therapy when possible. - If patient is on antipyretic or analgesic therapy, timing does not affect immunogenicity, but advise not to exceed recommended doses.